| Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. | |
| | |
MedLine Citation:
|
PMID: 20733101 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Ischemic cardiomyopathy is the major cause of heart failure and a significant cause of morbidity and mortality. The degree of left ventricular dysfunction in this setting is often out of proportion to the amount of overtly infarcted tissue, and how decreased delivery of oxygen and nutrients leads to impaired contractility remains incompletely understood. The Prolyl Hydroxylase Domain-Containing Protein (PHD) prolyl hydroxylases are oxygen-sensitive enzymes that transduce changes in oxygen availability into changes in the stability of the hypoxia-inducible factor transcription factor, a master regulator of genes that promote survival in a low-oxygen environment. METHODS AND RESULTS: We found that cardiac-specific PHD inactivation causes ultrastructural, histological, and functional changes reminiscent of ischemic cardiomyopathy over time. Moreover, long-term expression of a stabilized hypoxia-inducible factor alpha variant in cardiomyocytes also led to dilated cardiomyopathy. CONCLUSIONS: Sustained loss of PHD activity and subsequent hypoxia-inducible factor activation, as would occur in the setting of chronic ischemia, are sufficient to account for many of the changes in the hearts of individuals with chronic coronary artery disease. |
| | |
Authors:
|
Javid Moslehi; Yoji Andrew Minamishima; Jianru Shi; Donna Neuberg; David M Charytan; Robert F Padera; Sabina Signoretti; Ronglih Liao; William G Kaelin |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-08-23 |
Journal Detail:
|
Title: Circulation Volume: 122 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-08 Completed Date: 2010-09-29 Revised Date: 2011-07-25 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: United States |
Other Details:
|
Languages: eng Pagination: 1004-16 Citation Subset: AIM; IM |
Affiliation:
|
Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Basic Helix-Loop-Helix Transcription Factors / metabolism Cardiomyopathy, Dilated / metabolism*, physiopathology* Cell Hypoxia / physiology Heart Failure / metabolism, physiopathology Hypoxia-Inducible Factor 1, alpha Subunit / metabolism Mice Mice, Inbred C57BL Mice, Mutant Strains Mitochondria / metabolism Myocardial Stunning / metabolism*, physiopathology* Myocardium / metabolism Myocytes, Cardiac / cytology, enzymology* Neovascularization, Physiologic / physiology Phenotype Procollagen-Proline Dioxygenase / genetics*, metabolism |
| Grant Support | |
ID/Acronym/Agency:
|
K08HL097031/HL/NHLBI NIH HHS; R01 CA068490-15/CA/NCI NIH HHS; T32HL007604-24/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Basic Helix-Loop-Helix Transcription Factors; 0/Hif1a protein, mouse; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/endothelial PAS domain-containing protein 1; EC 1.14.11.2/Egln1 protein, mouse; EC 1.14.11.2/PHD3 protein, mouse; EC 1.14.11.2/Procollagen-Proline Dioxygenase |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year ...
Next Document: Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized c...